5 Key Takeaways

• 1

  A Phase 3 trial evaluated the travoprost intraocular implant's safety and efficacy for open-angle glaucoma or ocular hypertension.

• 2

  The trial compared fast-eluting and slow-eluting implants to timolol drops in reducing intraocular pressure (IOP).

• 3

  Both implant models achieved significant IOP reductions of 6.6 to 8.5 mmHg, comparable to timolol's 6.5 to 7.7 mmHg.

• 4

  Adverse events were more common in implant groups, with iritis and ocular hyperemia being the most frequent.

• 5

  The trial is ongoing to assess long-term efficacy and safety data after 3 years.